BioCentury
ARTICLE | Clinical News

FDA approves Agios' IDH1 inhibitor Tibsovo for AML

July 27, 2018 3:28 PM UTC

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to treat relapsed or refractory acute myelogenous leukemia (AML) in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first FDA-approved therapy for the indication.

An Agios spokesperson told BioCentury the company expected to launch Tibsovo at a wholesale acquisition cost (WAC) of $26,115 for a 30-day supply at a once-daily 500 mg dose...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.